Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPA-NORM study of empagliflozin versus usual care in non-diabetic chronic kidney disease with A1 albuminuria
jRCTs031260293Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial in chronic kidney disease (CKD) comparing Empagliflozin with Standard of care (2 arms). Primary endpoint: Total number of all-cause hospitalizations. Started Sep 2026; status: recruiting.
02
Drugs
empagliflozin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on jRCTs031260293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031260293.